Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (= 35 weeks gestational age), and children with hemodynamically significant CHD.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand SYNAGIS (Palivizumab) injection on prescription and Import License in Patient's Name only.
For Indian Patients, doctors and hospitals SYNAGIS (Palivizumab) injection can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.